Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy

Julie Barberio; Seoyoung C Kim; Miin Roh; James D Lewis; Rishi J Desai

doi:10.1093/crocol/otaa041

Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy

Crohns Colitis 360. 2020 Jun 4;2(3):otaa041. doi: 10.1093/crocol/otaa041. eCollection 2020 Jul.

Authors

Julie Barberio¹, Seoyoung C Kim^{1

2}, Miin Roh³, James D Lewis⁴, Rishi J Desai¹

Affiliations

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.
⁴ Department of Medicine, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Abstract

Background: Inflammatory bowel disease (IBD) patients may develop anterior uveitis.

Methods: An observational cohort of IBD patients followed new users of (1) tumor necrosis factor inhibitor versus nonbiologic agents or (2) adalimumab versus infliximab until occurrence of anterior uveitis or treatment change/discontinuation. Cox-proportional hazards models estimated hazard ratios in propensity score-matched cohorts of Crohn disease or ulcerative colitis patients.

Results: No statistically significant differences in the risk of uveitis were observed between initiators of nonbiologics and tumor necrosis factor inhibitor. Effect estimates for adalimumab versus infliximab were highly imprecise due to limited outcomes.

Conclusions: Uveitis risk was not different between IBD patients treated with immunosuppressives.

Keywords: adalimumab; inflammatory bowel disease; infliximab; uveitis.

Publication types

Review